Mansoura University
Al Mansurah, DK, 050, Egypt
NCT Number: NCT03649334
investigators aim to compare between anaesthetic regimens that included dual-agent (fentanyl and ketorolac) or (ketamine and ketorolac) analgesic therapy
Looking for future studies?
Notify Me2 year–7 year
All sexes
Interventional
Phase 4
Al Mansurah, DK, 050, Egypt
regarding patient registry; a prior G power analysis was done. Based on the assumption that the pain score in intramuscular ketamine group will be similar to similar to those in previously published data; forty children would be required per group to detect a difference of 30% in CHEOPS pain scores with a power of 90% (α =0.05, β =0.1)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
Time frame: for 60 minutes later admission to the post-anaesthesia care unit
Postoperative pain will be assessed by the CHEOP scale (Children's Hospital of Eastern Ontario Pain Scale)The scale includes six entries with an appropriate point evaluation focused on the character of crying (1-3 points), facial expressions (0-2 points), verbal reaction (0-2 points), position of the body (1-2 points), touch (1-2 points), and position of the legs (1-2 points). Minimum score is 4 (no pain) and maximum is 13 (maximum pain). Grades are summed together. CHEOPS has a minimum possible score of 4 points (no pain) to a maximum of 13 points (the worst pain).
When the postoperative pain score exceeded four, rescue analgesia was given with a 20mg/kg paracetamol suppository.
Time frame: at the baseline (after the induction of anesthesia and before administration of the drugs) then every 5min up to 20 minutes
Heart rate (beat/minute) using ECG monitoring
Time frame: at the baseline (after the induction of anesthesia and before administration of the drugs) then every 5min up to 20 minutes
systolic blood pressure (mmHg) using sphygmomanometer cuff
Time frame: during first 24 hours postoperative
The time to the first demand for rescue analgesic (minutes or hours)
Time frame: for 24 hours after surgery
Time frame: every 5 minutes during first 30 minutes of recovery
-emergence behavior will be measured using Aono's four point scale : (1) Asleep; (2) Awake but calm; (3) Agitated but consolable; and (4) Severely agitated and difficult to console and the highest-recorded value was recorded during the Post anesthesia care unit stay. Lowest score is 1 and highest score is 4 The higher score indicates more emergence agitation. For purposes of analysis, grades 1 and 2 in the scale of behavior were considered no agitation and grades 3 and 4 were considered the presence of agitation.
Time frame: during first 24 hours postoperative
Number of attacks of nausea and/or vomiting
Time frame: during first 24 hours postoperative
signs of respiratory difficulty:
Mansoura University
Other
Analgesic Efficacy of Intra-muscular Ketamine-ketorolac Versus Fentanyl- Ketorolac for Children Undergoing Bone Marrow Biopsy and Aspiration
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07131254
Hematologic Diseases, Hematologic Neoplasms
Ganzhou, Jiangxi, China
View Trial DetailsNCT06948981
Hematologic Diseases, Hematologic Neoplasms
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT03712878
Hematologic Diseases, Hematologic Neoplasms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04690205
Hematologic Diseases, Hematologic Malignancy
Boston, Massachusetts, United States
View Trial Details